- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 17, 2024
Finance
Public Equity Report: Erasca reboots, Telix plans NASDAQ listing
Plus: OnKure goes public via reverse merger, Monte Rosa and Allogene each raise $100M+, and Incyte’s $2B buyback
BioCentury | Nov 7, 2019
Product Development
AZ replants R&D roots in China, goes all-in on innovation
AstraZeneca throws weight behind China innovation while several peers focus on commercialization
BioCentury | Jun 3, 2019
Clinical News
June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more
BioCentury | Aug 23, 2018
Tools & Techniques
Computational tool prospectively predicts resistance to cancer drugs
BioCentury | Apr 24, 2018
Tools & Techniques
Merck adds affinity optimization to nanoscale synthesis system
BioCentury | Jan 5, 2018
Clinical News
BioMed Valley's ulixertinib leads to partial responses in Phase I for solid tumors
Items per page:
1 - 10 of 54